These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9591585)

  • 1. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies.
    Kobayashi H; Wu C; Yoo TM; Sun BF; Drumm D; Pastan I; Paik CH; Gansow OA; Carrasquillo JA; Brechbiel MW
    J Nucl Med; 1998 May; 39(5):829-36. PubMed ID: 9591585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.
    Camera L; Kinuya S; Garmestani K; Wu C; Brechbiel MW; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
    J Nucl Med; 1994 May; 35(5):882-9. PubMed ID: 8176477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
    Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW
    Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA).
    Camera L; Kinuya S; Garmestani K; Brechbiel MW; Wu C; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
    Eur J Nucl Med; 1994 Jul; 21(7):640-6. PubMed ID: 7957350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts.
    Roselli M; Milenic DE; Brechbiel MW; Mirzadeh S; Pippin CG; Gansow OA; Colcher D; Schlom J
    Cancer Biother Radiopharm; 1999 Jun; 14(3):209-20. PubMed ID: 10850305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts.
    Roselli M; Schlom J; Gansow OA; Raubitschek A; Mirzadeh S; Brechbiel MW; Colcher D
    J Nucl Med; 1989 May; 30(5):672-82. PubMed ID: 2785585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
    Carrasquillo JA; White JD; Paik CH; Raubitschek A; Le N; Rotman M; Brechbiel MW; Gansow OA; Top LE; Perentesis P; Reynolds JC; Nelson DL; Waldmann TA
    J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of metabolism on retention of indium-111-labeled monoclonal antibody in liver and blood.
    Kinuya S; Jeong JM; Garmestani K; Saga T; Camera L; Brechbiel MW; Gansow OA; Carrasquillo JA; Neumann RD; Paik CH
    J Nucl Med; 1994 Nov; 35(11):1851-7. PubMed ID: 7965168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
    Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a new DTPA-derivative chelator: comparative biodistribution and imaging studies of 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts.
    Camera L; Kinuya S; Garmestani K; Pai LH; Brechbiel MW; Gansow OA; Paik CH; Pastan I; Carrasquillo JA
    Nucl Med Biol; 1993 Nov; 20(8):955-62. PubMed ID: 8298575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.
    Shin IS; Lee SM; Kim HS; Yao Z; Regino C; Sato N; Cheng KT; Hassan R; Campo MF; Albone EF; Choyke PL; Pastan I; Paik CH
    Nucl Med Biol; 2011 Nov; 38(8):1119-27. PubMed ID: 21741258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
    Goodwin DA; Meares CF; Watanabe N; McTigue M; Chaovapong W; Ransone CM; Renn O; Greiner DP; Kukis DL; Kronenberger SI
    Cancer Res; 1994 Nov; 54(22):5937-46. PubMed ID: 7954426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
    Goodwin DA; Meares CF; Osen M
    J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
    Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
    Int J Cancer; 2011 Feb; 128(4):920-6. PubMed ID: 20473899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
    Price EW; Edwards KJ; Carnazza KE; Carlin SD; Zeglis BM; Adam MJ; Orvig C; Lewis JS
    Nucl Med Biol; 2016 Sep; 43(9):566-576. PubMed ID: 27419360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity.
    Kozak RW; Raubitschek A; Mirzadeh S; Brechbiel MW; Junghans RP; Gansow OA; Waldmann TA
    Cancer Res; 1989 May; 49(10):2639-44. PubMed ID: 2785435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.